Chugai Pharmaceutical Co Ltd
TSE:4519

Watchlist Manager
Chugai Pharmaceutical Co Ltd Logo
Chugai Pharmaceutical Co Ltd
TSE:4519
Watchlist
Price: 6 920 JPY 0.55% Market Closed
Market Cap: 11.6T JPY
Have any thoughts about
Chugai Pharmaceutical Co Ltd?
Write Note

Chugai Pharmaceutical Co Ltd
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Chugai Pharmaceutical Co Ltd
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Chugai Pharmaceutical Co Ltd
TSE:4519
PP&E Net
ÂĄ426.4B
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
12%
Takeda Pharmaceutical Co Ltd
TSE:4502
PP&E Net
ÂĄ1.9T
CAGR 3-Years
9%
CAGR 5-Years
5%
CAGR 10-Years
13%
Daiichi Sankyo Co Ltd
TSE:4568
PP&E Net
ÂĄ458.4B
CAGR 3-Years
17%
CAGR 5-Years
14%
CAGR 10-Years
4%
Otsuka Holdings Co Ltd
TSE:4578
PP&E Net
ÂĄ578.8B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
6%
S
Shionogi & Co Ltd
TSE:4507
PP&E Net
ÂĄ121.1B
CAGR 3-Years
7%
CAGR 5-Years
10%
CAGR 10-Years
4%
Astellas Pharma Inc
TSE:4503
PP&E Net
ÂĄ315.3B
CAGR 3-Years
6%
CAGR 5-Years
4%
CAGR 10-Years
5%
No Stocks Found

Chugai Pharmaceutical Co Ltd
Glance View

Market Cap
11.4T JPY
Industry
Pharmaceuticals
Economic Moat
Narrow

Chugai Pharmaceutical Co., Ltd., a pivotal player in the pharmaceutical industry, finds its roots deeply intertwined with innovations in biotechnology. Established in Tokyo, Chugai has carved out a niche by focusing on the development and distribution of prescription pharmaceuticals tailored to address some of the most challenging medical conditions. The company's collaboration with Roche, a global healthcare leader, has strategically positioned it within the Roche Group, allowing access to an expansive trove of research and development resources. This partnership amplifies Chugai's innovative efforts, particularly in biologics and oncology, where they develop antibodies and therapies that have been instrumental in advancing clinical treatments worldwide. The synergy of Chugai's science-driven approach, coupled with Roche's global reach, has fostered a dynamic research environment that continues to push the boundaries of medical treatment possibilities. Revenue streams for Chugai are primarily anchored in the research, development, and subsequent commercialization of novel pharmaceuticals. The company gains its financial strength through successful product launches, sustained sales of flagship products, and collaborative research agreements. Chugai's extensive pipeline, particularly in the fields of oncology, immunology, and renal diseases, reflects a strategic emphasis on addressing unmet medical needs, with a considerable portion of their earnings reinvested into further research. Additionally, strategically negotiated licensing agreements allow Chugai to bolster its financial health by sharing its innovations with other industry players, maximizing distribution channels while ensuring a steady cash influx. Through this intricate balance of innovation, strategic partnerships, and a robust commercial network, Chugai not only thrives within the competitive pharmaceutical landscape but also contributes significantly to the global healthcare ecosystem.

Intrinsic Value
4 526.93 JPY
Overvaluation 35%
Intrinsic Value
Price

See Also

What is Chugai Pharmaceutical Co Ltd's PP&E Net?
PP&E Net
426.4B JPY

Based on the financial report for Sep 30, 2024, Chugai Pharmaceutical Co Ltd's PP&E Net amounts to 426.4B JPY.

What is Chugai Pharmaceutical Co Ltd's PP&E Net growth rate?
PP&E Net CAGR 10Y
12%

Over the last year, the PP&E Net growth was 2%. The average annual PP&E Net growth rates for Chugai Pharmaceutical Co Ltd have been 9% over the past three years , 11% over the past five years , and 12% over the past ten years .

Back to Top